FII Holdings

LINCOLN PHARMACEUTICALS LTD.

NSE : LINCOLNBSE : 531633ISIN CODE : INE405C01035Industry : Pharmaceuticals & DrugsHouse : Private
BSE585.40-7.35 (-1.24 %)
PREV CLOSE ( ) 592.75
OPEN PRICE ( ) 596.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2180
TODAY'S LOW / HIGH ( )582.50 600.90
52 WK LOW / HIGH ( )328.75 754.25
NSE586.05-7.1 (-1.2 %)
PREV CLOSE( ) 593.15
OPEN PRICE ( ) 598.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 586.05 (2)
VOLUME 39144
TODAY'S LOW / HIGH( ) 582.10 603.85
52 WK LOW / HIGH ( )329.55 755.15
upfii downfii 
Current Quarter
Prev Quarter
Company Quarter Ended 202312 % of Share Quarter Ended 202309 % of Share Changeupfii

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.